Trial reportPharmacogenetics and genomics2013
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.
Trial report in Pharmacogenetics and genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Pooled it
- Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.Pharmacogenetics and genomics · 2017Pooled it
- Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema.The Journal of allergy and clinical immunology · 2018Trial
- ACE inhibitor-induced isolated intestinal angioedema mimicking functional bowel disorder: a case report.BMC gastroenterology · 2026Article
- A GWAS of angiotensin-converting enzyme inhibitor-induced angioedema in a South African population.The journal of allergy and clinical immunology. Global · 2025Article
- A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.NPJ genomic medicine · 2025Review
- Whole Exome Sequencing in Drug-Induced Angioedema Caused by Angiotensin-Converting Enzyme Inhibitors: A Pilot Study in Five Patients.Journal of clinical medicine · 2025Article
- Risk Assessment and Personalized Treatment Options in Inherited Dilated Cardiomyopathies: A Narrative Review.Biomedicines · 2024Review
- Angiotensin-Converting Enzyme Inhibitors and Other Medications Associated With Angioedema.Cureus · 2023Review
- Bradykinin Metabolism and Drug-Induced Angioedema.International journal of molecular sciences · 2023Review
- Antihypertensives associated adverse events: a review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations.Frontiers in pharmacology · 2023Review
- Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci.European heart journal · 2022Article
- Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion.Frontiers in cardiovascular medicine · 2022Article
- Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs.Diseases (Basel, Switzerland) · 2021Review
- Genomic markers associated with successful treatment of hypertension with lisinopril: A pilot study.International journal of clinical pharmacology and therapeutics · 2021Observational
- Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine.Clinical reviews in allergy & immunology · 2021Review
- Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema.Clinical pharmacology and therapeutics · 2020Article
- Genetics of dilated cardiomyopathy: practical implications for heart failure management.Nature reviews. Cardiology · 2020Review
- Corrigendum: Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics.Frontiers in genetics · 2020Article
- Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics.Frontiers in genetics · 2019Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 9 institutions in 4 countries.
Funding
Abstract
objectiveThe objective of this study was to identify genetic variants associated with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. PARTICIPANTS AND
methodsWe carried out a genome-wide association study in 175 individuals with ACE inhibitor-associated angioedema and 489 ACE inhibitor-exposed controls from Nashville (Tennessee) and Marshfield (Wisconsin). We tested for replication in 19 cases and 57 controls who participated in Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
resultsThere were no genome-wide significant associations of any single-nucleotide polymorphism (SNP) with angioedema. Sixteen SNPs in African Americans and 41 SNPs in European Americans were associated moderately with angioedema (P<10) and evaluated for association in ONTARGET. The T allele of rs500766 in PRKCQ was associated with a reduced risk, whereas the G allele of rs2724635 in ETV6 was associated with an increased risk of ACE inhibitor-associated angioedema in the Nashville/Marshfield sample and ONTARGET. In a candidate gene analysis, rs989692 in the gene encoding neprilysin (MME), an enzyme that degrades bradykinin and substance P, was significantly associated with angioedema in ONTARGET and Nashville/Marshfield African Americans.
conclusionUnlike other serious adverse drug effects, ACE inhibitor-associated angioedema is not associated with a variant with a large effect size. Variants in MME and genes involved in immune regulation may be associated with ACE inhibitor-associated angioedema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.